and pRb, two components of a key G1/S regulatory pathway, and tumor suppressors commonly targeted in oncogenesis, are among the candidates for gene therapy of cancer. Wild-type p16 and a constitutively active pRb Dcdk mutant both blocked G1 in shortterm experiments, but only p16 imposed a sustained G1 arrest. Unexpectedly, cells conditionally exposed to pRb Dcdk entered S phase after 2 days, followed by endoreduplication between days 4 ± 6. The distinct phenotypes evoked by p16 vs pRb Dcdk appear mediated by cyclin E/CDK2 which, while active in the pRb Dcdk -expressing cells, became rapidly inhibited through restructuring diverse cyclin/CDK/p21 complexes by p16. These results provide novel insights into the roles of p16, pRb and cyclin E in G1/S control and multistep oncogenesis, with implications for gene therapy strategies.
Introduction
pRb is an archetypal tumor suppressor and cell cycle regulator that controls commitment to progress from G1 to S phase, at least in part by repressing the activity of the E2F transcription factors known to promote cell proliferation (Weinberg, 1995) . In response to mitogens, pRb's growth suppressive activity is cancelled by phosphorylation in late G1, a process critically dependent on cyclin D-associated kinases (Weinberg, 1995; Bartek et al., 1996; Sherr, 1996) . Both the D-type cyclins and their partner kinases CDK4/6 have protooncogenic properties, and their activity is carefully regulated at multiple levels including negative control by two families of CDK inhibitors (Sherr and Roberts, 1995) . While members of the INK4 family interact speci®cally with CDK4 and CDK6, the Cip/Kip inhibitors p21, p27, and p57 inhibit a broader spectrum of CDKs. Prominent among the INK4 CDK inhibitors is the product of the CDKN2 gene, p16 INK4a , a tumor suppressor whose inactivation through deletion, mutation or promoter methylation contributes to molecular pathogenesis of diverse types of tumors (Sherr and Roberts, 1995; Merlo et al., 1995; Kamb, 1998) . The interplay between p16, cyclin D/ CDKs, and pRb/E2F together constitute a functional unit collectively known as the`Rb pathway' Sherr, 1996) . Each of the major components of this mechanism may become deregulated in cancer, and accumulating evidence points to the Rb pathway as a candidate obligatory target in multistep oncogenesis of possibly all human tumor types. The latter notion has recently inspired considerable eorts to develop novel cancer therapeutics targeting the G1/S control, including gene therapy approaches aimed at inhibition of cyclin-CDK activities and induction of apoptosis (Kamb, 1998; Sandig et al., 1997) . A prerequisite for manipulating such regulatory mechanism in a predictable fashion is clearly to better understand cellular responses to long-term blockade of the Rb pathway. As this critical information cannot simply be deduced from the available data obtained in short-term, transient experiments, we have now examined the phenotypes and underlying molecular events in cells exposed to sustained expression of either phosphorylation-de®cient, constitutively active pRb, or wild-type p16.
Results and Discussion
Distinct abilities of p16 versus pRb to block G1 of human and rat cells in extended transient gene transfer experiments Both wild-type p16 and nonphosphorylatable mutant pRb cause a G1 arrest of mammalian cells when expressed in transient transfections with commonly used follow-up period of 24 ± 36 h , consistent with the widely accepted role of pRb as a universal`gate-keeper' of G1/S transition (Weinberg, 1995) . To examine the eects of constitutively active pRb and p16 on cell cycle progression over an extended period of time, we performed transient gene transfer experiments with human U-2-OS and R12 cells followed for 60 ± 72 h, a maximum period of reliable expression of the transgenes. These two cell types are among the most frequently used models in the cell cycle ®eld, well de®ned in terms of proliferation parameters, and with preserved wild-type pRb and p53 . As can be seen from the time course¯ow cytometry analyses of U-2-OS cells ( Figure  1a ), ectopic expression of either the phosphorylation de®cient allele of pRb (designated pRb Dcdk ) or wild-type p16 resulted in pronounced accumulation of cells in G1 at 24 h after transfection. Whereas the G1 arrest imposed by p16 remained unchanged for the duration of the entire 72-h experiment, cells exposed to the pRb mutant began to enter S phase at 48 h post transfection, with the majority of cells synthesizing their DNA at the 72-h time point (Figure 1a ). The inability of constitutively active pRb to prevent G1/S transition under conditions when p16 could impose a long-term G1 blockade was unexpected and not easily reconciled with the fact that p16 is a component within the same biochemical pathway, operating upstream of pRb (Weinberg, 1995; Bartek et al., 1996; Sherr, 1996) .
To verify the observed eects in another species and a dierent cell type, we performed analogous experiments with the rat R12 cells pre-synchronized in quiescence by serum starvation. Control non-injected cells started massive entry into S phase between 12 and 24 h after serum addition (Figure 1b) , a process only marginally delayed by ectopic expression of wild-type pRb which appears to be eciently neutralized by endogenous cyclin-CDKs. Reminiscent of the data with U-2-OS cells, R12 ®broblasts expressing ectopic p16 did not initiate DNA synthesis for the entire duration of the experiment, in contrast to cells exposed to the pRb Dcdk mutant which was able to considerably delay, but not prevent, the S phase entry (Figure 1b) .
These data point to previously unsuspected differences in the relative abilities of p16 and pRb to arrest mammalian cells in G1, apparently manifest in both exponentially growing cells (U-2-OS) and cells entering the cell cycle from quiescence (R12). Parallel immunostaining of cells by antibodies to the HA tag and human p16 at the corresponding time points con®rmed that both proteins remained expressed for comparable periods of time, thereby excluding the possibility that the observed eects were attributable to dierential expression and/or stability of the ectopic pRb and p16, respectively. To further elucidate these intriguing observations, we set out to construct cell clones in Figure 1 pRb Dcdk retards G1/S transition while p16 induces a sustained G1 arrest. (a) pRb Dcdk (left) and p16 (right) were transiently expressed in U-2-OS cells together with the surface marker CD20, and DNA pro®les of productively transfected cells evaluated by¯ow cytometry at the indicated time-points, compared with control cells transfected with empty vector. Numbers above the histograms indicate percentage of cells in G1. (b) R12 cells serum-starved for 48 h were microinjected with the indicated expression plasmids (25 mg/ml), stimulated by medium with 10% serum, bromodeoxyuridine (100 mg/ml) added 12 h before each time-point, and incorporation evaluated by immunostaining in productively-injected cells (Lukas et al., 1995a) which expression of either transgene could be rendered conditional at the whole population level.
Construction and characterization of U-2-OS clones with regulatable expression of constitutively active pRb or p16
Clones of U-2-OS cells with tetracycline-repressible expression of either the pRb Dcdk or the wild-type p16 transgene were isolated using standard procedures, and basic characterization of two representative clones is shown in Figure 2 . Tight and regulatable control over the expression of either transgene is documented by no detectable ectopic protein in the presence of tetracycline in the culture medium, in contrast to the high levels of pRb Dcdk (Figure 2a ) or p16 ( Figure 2c , top panel) detectable between days 1 ± 6 upon removal of tetracycline. Parallel immuno¯uorescence time-course analyses showed no leakage of the transgenes in the repressed state, and rapid, uniform expression at the protein level in more than 90% of cells after derepression (data not shown). To con®rm that the induced proteins were functional, the ability of pRb Dcdk to repress transactivation by endogenous E2F, and the ability of p16 to prevent formation of cyclin D-CDK4/ 6 complexes and phosphorylation of endogenous pRb were examined. The quantitative reporter assay to monitor E2F-dependent transactivation in live cells 
revealed high luciferase activities in the pRb
Dcdk clone cultured with tetracycline, in sharp contrast to no detectable activity following expression of the transgene (Figure 2b) . Thus, the pRb Dcdk was active and it remained fully competent to repress E2F-dependent transactivation for the duration of the 6-day experiment. That the p16 transgene expressed in the other clone was functional was evident from the ecient binding of the induced p16 protein to endogenous CDK4 and CDK6 (Figure 2c , top panel), thereby disrupting and/or preventing formation of endogenous complexes between cyclin D1 and these two kinases (Figure 2c , middle panel), as well as from the disappearance of phosphorylated, more slowly migrating species of endogenous pRb (Figure 2c , bottom panel), and from inhibition of E2F activity examined by the in vivo luciferase reporter assay (data not shown). Although due to space limitations only data for two clones are shown here and will be documented below, analogous results were obtained for at least one additional clone for each transgene, thereby excluding any exceptional clonal eects.
Long-term, conditional expression of p16, but not of constitutively active pRb, leads to sustained G1 arrest Given the distinct eects on cell cycle progression of pRb Dcdk versus p16 in the initial transient experiments (Figure 1 ), we wished to examine the impact of either transgene on proliferation of the newly constructed U-2-OS clones. Whereas the clones grew exponentially in the presence of tetracycline in the medium, cell proliferation ceased completely when expression of pRb Dcdk or p16 were derepressed (Figure 3a) . The issue whether the observed growth curves simply re¯ected homogenous cell cycle arrest, a balance between proliferation and cell death, or impaired yet detectable progression through some of the cell cycle transitions was then addressed by¯ow cytometry. No signi®cant apoptosis was detected in any of the clones expressing pRb Dcdk or p16, and consistent with the transient experiments, the cells exposed to p16 remained largely arrested in G1 for the entire 6-day period (Figure 3b ). The¯ow cytometry patterns were quite dierent in the cells induced to express pRb Dcdk , however, in that more than 90% of cells progressed from G1 into S phase between days 2 and 6 after tetracycline removal ( Figure  3b ). In addition, a signi®cant proportion of the cells exposed to nonphosphorylatable pRb showed increased ploidy, with DNA contents exceeding 4N between day 4 and 6 of the time course (Figure 3b) . The latter phenomenon is characteristic of cells undergoing endoreplication, and together with the data from our initial transient experiments these results reveal clear dierences between the long-term eects of p16 versus constitutively active pRb. Thus, while p16 imposed a sustained cell cycle arrest in G1, cells expressing active pRb Dcdk were able to enter S phase and even re-initiated DNA synthesis uncoupled from mitosis, resulting in aberrant ploidy exceeding 4N.
Biochemical eects on cyclin-CDKs indicate a dual role of p16 in negative regulation of G1/S transition To gain insights into the biochemical mechanisms underlying the distinct cell cycle phenotypes evoked by inducible pRb
Dcdk and p16, we next examined protein levels and function of a series of cell cycle regulators critical for timely progression through G1/S. While levels of cyclin E were only moderately aected and CDK2 remained virtually constant in either pRb Dcdk -or p16-expressing clones, cyclin A protein abundance decreased rapidly (Figure 4a) . Expression of the CDK inhibitor p21 was elevated at days 4 ± 6 after derepression of the transgenes (Figure 4a ), whereas p27 remained at very low levels throughout the experiment (data not shown). More dramatic dierences between the U-2-OS clones expressing pRb Dcdk or p16 became obvious upon analyses of cyclin-CDK complexes and associated kinase activities. First, considerably more rapid and abundant association of p21 with cyclin E was detected in the p16-, as compared with the pRb Dcdk -expressing cells (Figure 4b) . Second, large amounts of the inactive form of CDK2 were complexed to cyclin D in the p16-, but not pRb Dcdk -expressing clones, ( Figure  4c ). Third, while cyclin A-associated kinase activities dropped dramatically in all clones, cyclin E-dependent kinase activity remained relatively high during the initial 2 ± 3 days following induction of pRb Dcdk when compared to rapid inhibition in the p16-expressing cells (Figure 4d ). These results show that p16 not only prevents activation of cyclin D/CDKs but also leads to rapid inhibition of cyclin E/CDK2, an eect likely underlying the substantially longer G1 arrest than the transient cell cycle block imposed by constitutively active pRb.
Conceptual implications for G1/S control and oncogenesis
The present study demonstrates that long-term exposure to p16 and constitutively active pRb elicit distinct cell cycle phenotypes, and the biochemical analyses suggest the likely targets that mediate these unexpected eects. First, the fact that mitogenstimulated cells eventually entered S phase despite active pRb that repressed E2F-dependent transcription suggests existence of a G1/S regulatory pathway, parallel to the classical cyclin D/CDK/pRB/E2F axis Sherr, 1996) , and indicates that expression of cyclin E, a known target of E2F (Ohtani al., 1995) , can reach physiologically relevant levels independently of E2F activity. Second, p16 proved to be a considerably more potent inhibitor of G1/S transition than pRb Dcdk , a signi®cant functional distinction likely attributable to a combination of direct and indirect eects of p16 on composition and activity of cyclin/CDK complexes. Apart from the known disruption of cyclin D/CDK4(6) complexes (Sherr and Roberts, 1995) , we demonstrate here that p21 released from such complexes by p16 binds to CDK2, and the liberated cyclin D sequesters CDK2 in inactive complexes, thereby contributing to ecient inhibition of cyclin E-dependent kinase activity. In a recent study published upon completion of our present work, Jiang et al. (Jiang et al., 1998) showed redistribution of the p27 CDK inhibitor from cyclin D-to cyclin E-containing complexes in response to p16. Although p27 levels were very low in the cells studied here, it appears that dependent on cellular environment, inhibition of cyclin E/CDK2 by redirecting p27 (Jiang et al., 1998) or p21 (this study), and possibly by sequestration of CDK2 in an inactive state by cyclin D (this study), may represent an integral part of the powerful growth-suppressing eect of the p16 tumor suppressor in Rb-positive cells. On the other hand, cyclin E/CDK2 is rate-limiting and essential for G1/S progression independent of pRb Sherr and Roberts, 1995; Ohtsubo et al., 1995) , while the ability of p16 to arrest G1 requires functional pRb (Weinberg, 1995; Bartek et al., 1996; Sherr, 1996; Lukas et al., 1995a; Koh et al., 1995) , raising the question of why is the indirect, cyclin E/CDK2-inhibitory eect of p16 not manifest in Rb-negative human tumors. We believe at least three phenomena could explain the failure to inhibit G1 by p16 in cancer cells lacking functional pRb: (i) aberrantly low levels of the D-type cyclins (Lukas et al., 1994) ; (ii) elevated abundance of cyclin E as a consequence of deregulated E2F (Herrera et al., 1996) ; and (iii) very low levels of p21 as a consequence of p53 mutations which almost invariably accompany loss of Rb. Although none of these changes that evolve during multistep oncogenesis is likely to prevent the ability of p16 to directly act on cyclin D-dependent complexes, we expect that they would considerably decrease or eliminate the indirect eects of the INK4 family of CDK inhibitors (Sherr and Roberts, 1995; Jiang et al., 1998; ReynisdoÂ ttir et al., 1995; Planas-Silva and Weinberg, 1997) on cyclin E/CDK2. The recent demonstration that ectopic expression of cyclin E can rescue the p16-mediated G1 arrest Alevizopoulos et al., 1997) is also consistent with such interpretation. Finally, we believe that our present ®ndings may assist in designing future gene therapy strategies, in that at least Rb-positive malignancies might respond more decisively to p16 than to active pRb, with an additional bene®t of avoiding the potentially hazardous occurrence of aneuploid cells. In any case, targeting both the cyclin D/CDK/pRb/E2F pathway and the cyclin E-dependent kinase activity may turn out to be the way to eciently block cancer cell growth, possibly with concomitant induction of cell death by p53 or other pro-apoptotic regulators.
Materials and methods

Plasmids and gene transfer
HA-tagged, phosphorylation-de®cient mutant of pRb (pRb Dcdk ) lacking ten CDK consensus sites was excised from pECE-pRb Dcdk with EcoRI and SauI, blunt-ended and cloned into EcoRV site of the pBI tetracycline-responded plasmid (Clonetech, Palo Alto, CA, USA). Expression plasmid for HA-tagged wild-type murine pRb, pECE-pRbDB/X, was provided by P Hamel. Plasmids pBABE puro, pCMV-CD20 and the pGL3-TATA-6xE2F reporter were described . p16 cDNA was excised from pXp16 (Lukas et al., 1995a) using BamHI and HindIII, blunt-ended and cloned into EcoRV site of the pBI plasmid. Transient transfection and microinjection were performed essentially as described (Lukas et al., 1995a) .
Cell culture
U-2-OS is a human osteogenic sarcoma cell line (#ATTC HTB 96). Clone U-2-OS-TA (provided by K Helin) containing stably integrated tetracycline-regulated transcriptional activator (tet-VP16) and neomycine-resistance gene was transfected with pBI vectors for pRb Dcdk or p16 together with the pBABE-puro plasmid at 10 : 1 ratio. Puromycin-resistant clones were grown in DME (Gibco) with 10% fetal calf serum and penicillin (10 U/ml), streptomycin (10 U/ml), geneticin (G418; 400 mg/ml), puromycin (1 mg/ml) and tetracycline (2 mg/ml). For de-repression, cell monolayers were washed three times in PBS, trypsinized and plated into tetracycline-free media. Cells for the counting experiments were seeded at 1.5610 5 per 60 mm dish, and counted in triplicate every 48 h until day 6 of induction. R12 cells expressing tet-VP16 were derived from Rat-1 diploid ®broblasts .
Flow cytometry
Cells were trypsinized and ®xed in 70% cold methanol for 20 min, washed in PBS, and incubated for 30 min at 378C in a PI buer (10 mM Tris-HCl, pH 7.5; 5 mM MgCl 2 ; 50 mg/ml propidium iodide) containing 10 mg/ml RNase A. The stained cells were acquired by the FACSCalibur¯ow cytometer (Becton Dickinson; San Jose, CA, USA) using CellQuest software, with cell doublets and aggregates eliminated from all analyses. The DNA distribution (FL2-A parameter) was analysed by ModFit software. Sorting and DNA analysis of transiently transfected cells co-expressing the CD-20 cell surface antigen were performed as described (Lukas et al., 1995a) .
Immunochemical techniques, kinase and reporter assays
Monoclonal antibodies used in this study: 245 against pRb (Pharmingen, San Diego, CA, USA); HE12 and HE172 against cyclin E for immunoblots and immunoprecipitation, respectively (provided by SI Reed); 5D4 to cyclins D1 and D2 (provided by M Seto); 12CA5 to the hemagglutinin epitope ; DCS-50 against p16 (Lukas et al., 1995a) ; DCS-60 and DCS-61 to p21; and DCS-35 to CDK4 (our unpublished data). Rabbit antisera to cyclin A for kinase assays (provided by M Pagano) and immunoblots (C24230; Transduction Laboratories; Lexington, KY, USA; Western blotting); to CDK2 (SC-163; Santa Cruz Biotechnology); and CDK4 (SC-177; Santa Cruz Biotechnology). Anti-BrdU FITC and anti-CD20 FITC were purchased from Becton Dickinson. Immunoblotting, immunostaining and immunoprecipitation methods were described earlier (Lukas et al., 1995a,b) . Kinase assays were performed as reported except for using histone H1 (2.5 mg) as substrate. The non-invasive cell luminescence imaging assay to monitor E2F-dependent transcription was performed and quanti®ed as described .
